Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
Vaccine Development and Global Health
share announcement

Vaccine Development and Global Health

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines and Public Health".

Deadline for manuscript submissions: 31 January 2026 | Viewed by 4466

Special Issue Editors

Dr. Anna Paczkowska

E-Mail Website
Guest Editor
Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Poznan, Poland
Interests: infectious diseases; pharmacovigilance; COVID-19 pandemic; pharmacotherapy; biotechnology drugs
Special Issues, Collections and Topics in MDPI journals
Dr. Karolina Hoffmann

E-Mail Website
Guest Editor
Department of Internal Diseases, Metabolic Disorders and Arterial Hypertension, Poznan University of Medical Sciences, Szamarzewskiego 84 Street, 60-572 Poznan, Poland
Interests: internal diseases; metabolic disorders; arterial hypertension; public health
Dr. Krzysztof Kus

E-Mail Website
Guest Editor
Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, 61-701 Poznań, Poland
Interests: pharmacology; pharmacoeconomics; medical and drug databases; quality of life; EBM; RWE; therapy costs
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Facilitating vaccine development and global health is essential in protecting humans and animals from a range of diseases. Novel and proactively designed development, regulatory, and policy approaches are needed to deliver many vaccines and help sustain current vaccine programs successfully. With rates of vaccine-preventable diseases such as measles and polio rising, the gaps in immunization indicate more significant global vulnerabilities to disease outbreaks. The vital role of vaccines in responding to COVID-19 underscores the relevance of strong and equitable immunization programs and the need for novel vaccine development, such as multi-pathogen combination vaccines, e.g., more than one vaccine in the same injection to tackle multiple diseases.

This approach is compelling because it could substantially increase adherence to vaccination schedules through easier delivery. This Special Issue will discuss topics, advantages, and potential challenges of issues such as vaccine delivery, vaccination schedules, routes of administration, and the health impact. Ways to potentially increase good vaccine outcomes, including a more significant and equitable global impact to improve health and economic value, will be considered.

Dr. Anna Paczkowska
Dr. Karolina Hoffmann
Dr. Krzysztof Kus
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • next-generation vaccines
  • clinical efficacy of vaccines
  • vaccine safety
  • treatment methods for civilization diseases
  • public health
  • prevention of civilization diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 310 KiB  
Article
Beyond Vaccination: Exploring Young Adults’ Awareness, Knowledge, and Attitudes Related to Sexually Transmitted Infections in Romania
by Alexandra-Ioana Roșioară, Bogdana Adriana Năsui, Nina Ciuciuc, Dana Manuela Sîrbu, Daniela Curșeu, Romulus Florian Oprica, Codruța Alina Popescu, Rodica Ana Ungur, Tamara Cheșcheș and Monica Popa
Vaccines 2025, 13(3), 322; https://doi.org/10.3390/vaccines13030322 - 18 Mar 2025
Viewed by 1140
Abstract
Background and Objectives: Romania has the highest rate of cervical cancer in Europe. The aim of this study is to measure the level of sexual health knowledge among participants and determine the extent to which factors such as age, gender, education level, access [...] Read more.
Background and Objectives: Romania has the highest rate of cervical cancer in Europe. The aim of this study is to measure the level of sexual health knowledge among participants and determine the extent to which factors such as age, gender, education level, access to sexual health resources, and cultural background influence their knowledge. Materials and Methods: A cross-sectional study was conducted on 1089 Romanian youth participants aged 18–35 years. A self-administered online questionnaire was used concerning the level of knowledge relating to STIs, contraception methods, and preventive attitudes during the 2023–2024 academic year. Results: Most of the participants (93,8%) scored a “good-to-excellent” STI level of knowledge. Despite this, 71.9% of the responders had never taken an HIV test, and 63.5% had never been tested for other STIs. Logistic regression analysis revealed a direct association between higher STI knowledge levels among respondents with age (p < 0.001), underage sexual debuts (p = 0.018), greater parental education (p = 0.016), and those who studied health sciences (p < 0.001). Conclusions: This study highlights the critical need for health communication campaigns to enhance STI knowledge and vaccine literacy to improve the vaccination rates among young people in Romania. The identified knowledge gaps, frequent misconceptions, and barriers to STI testing underscore the importance of comprehensive sexual health education, public health initiatives for reducing the stigma associated with STIs, and improved access to healthcare services for young people. Full article
(This article belongs to the Special Issue Vaccine Development and Global Health)

Review

Jump to: Research

32 pages, 1404 KiB  
Review
Next-Generation Vaccine Platforms: Integrating Synthetic Biology, Nanotechnology, and Systems Immunology for Improved Immunogenicity
by Majid Eslami, Bahram Fadaee Dowlat, Shayan Yaghmayee, Anoosha Habibian, Saeedeh Keshavarzi, Valentyn Oksenych and Ramtin Naderian
Vaccines 2025, 13(6), 588; https://doi.org/10.3390/vaccines13060588 - 30 May 2025
Viewed by 1256
Abstract
The emergence of complex and rapidly evolving pathogens necessitates innovative vaccine platforms that move beyond traditional methods. This review explores the transformative potential of next-generation vaccine technologies, focusing on the combined use of synthetic biology, nanotechnology, and systems immunology. Synthetic biology provides modular [...] Read more.
The emergence of complex and rapidly evolving pathogens necessitates innovative vaccine platforms that move beyond traditional methods. This review explores the transformative potential of next-generation vaccine technologies, focusing on the combined use of synthetic biology, nanotechnology, and systems immunology. Synthetic biology provides modular tools for designing antigenic components with improved immunogenicity, as seen in mRNA, DNA, and peptide-based platforms featuring codon optimization and self-amplifying constructs. At the same time, nanotechnology enables precise antigen delivery and controlled immune activation through engineered nanoparticles such as lipid-based carriers, virus-like particles, and polymeric systems to improve stability, targeting, and dose efficiency. Systems immunology aids these advancements by analyzing immune responses through multi-omics data and computational modeling, which assists in antigen selection, immune profiling, and adjuvant optimization. This approach enhances both humoral and cellular immunity, solving challenges like antigen presentation, response durability, and vaccine personalization. Case studies on SARS-CoV-2, Epstein–Barr virus, and Mycobacterium tuberculosis highlight the practical application of these platforms. Despite promising progress, challenges include scalability, safety evaluation, and ethical concerns with data-driven vaccine designs. Ongoing interdisciplinary collaboration is crucial to fully develop these technologies for strong, adaptable, globally accessible vaccines. This review emphasizes next-generation vaccines as foundational for future immunoprophylaxis, especially against emerging infectious diseases and cancer immunotherapy. Full article
(This article belongs to the Special Issue Vaccine Development and Global Health)
►▼ Show Figures

Figure 1

17 pages, 267 KiB  
Review
The Application of mRNA Technology for Vaccine Production—Current State of Knowledge
by Anna Paczkowska, Karolina Hoffmann, Agata Andrzejczak, Weronika Faustyna Pucek, Dorota Kopciuch, Wiesław Bryl, Elżbieta Nowakowska and Krzysztof Kus
Vaccines 2025, 13(4), 389; https://doi.org/10.3390/vaccines13040389 - 4 Apr 2025
Viewed by 1566
Abstract
Over the past 20 years, intensive research has been conducted on the development of therapeutic mRNA, leading to numerous discoveries that have enabled its use in therapy. The main achievements in this field include increasing mRNA stability, reducing its immunogenicity (i.e., its ability [...] Read more.
Over the past 20 years, intensive research has been conducted on the development of therapeutic mRNA, leading to numerous discoveries that have enabled its use in therapy. The main achievements in this field include increasing mRNA stability, reducing its immunogenicity (i.e., its ability to trigger an immune response), and solving the challenge of delivering mRNA into cells—all to achieve a therapeutic effect. The aim of this study was to review the scientific literature on the use of mRNA technology in the production of vaccines. Various methods of applying mRNA technology that could potentially be introduced into clinical practice in the future are described. A detailed analysis was conducted on the approved COVID-19 vaccines developed by Pfizer/BioNTech (New York, NY, USA) and Moderna (Kirkland, QC, Canada), as their introduction marked a groundbreaking moment in the advancement of mRNA technology. This study was based on the latest scientific literature from reputable publishers and medical databases such as PubMed and ClinicalTrials. In conclusion, mRNA technology is currently experiencing rapid development, significantly driven by the ongoing COVID-19 pandemic. The application of this technology holds great potential not only for vaccines against infectious diseases but also for cancer treatment. However, further research is necessary to facilitate its broader clinical implementation. Full article
(This article belongs to the Special Issue Vaccine Development and Global Health)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop